Specifically geared to personnel in the pharmaceutical and biotechnology industries, this book describes the basics and challenges of oral bioavailability – one of the most significant hurdles in drug discovery and development.
• Describes approaches to assess pharmacokinetics and how drug efflux and uptake transporters impact oral bioavailability
• Helps readers reduce the failure rate of drug candidates when transitioning from the bench to the clinic during development
• Explains how preclinical animal models – used in preclinical testing – and in vitro tools translate to humans, which is an underappreciated and complicated area of drug development
• Includes chapters about pharmacokinetic modelling, the Biopharmaceutics Drug Disposition Classification System (BDDCS), and the Extended Clearance Classification System (ECCS)
• Has tutorials for applying strategies to medicinal chemistry practices of drug discovery/development
|
1 Drug Pharmacokinetics and Toxicokinetics |
|
|
1 | (34) |
|
2 GIT Anatomy and Physiology and Drug Oral Bioavailability: Impact of Species Differences |
|
|
35 | (42) |
|
3 Drug Routes of Excretion |
|
|
77 | (62) |
|
4 Physicochemical and Biopharmaceutical Properties that Affect Drug Absorption of Compounds Absorbed by Passive Diffusion |
|
|
139 | (34) |
|
5 Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First-Pass Effect |
|
|
173 | (30) |
|
6 Impact of Intestinal Efflux Transporters on Oral Absorption |
|
|
203 | (66) |
|
7 Impact of Influx Transporters on Drug Absorption |
|
|
269 | (40) |
|
8 Extended Clearance Classification System (ECCS) and its Utility in Predicting Clearance Rate-Determining Step in Drug Discovery |
|
|
309 | (22) |
|
9 In Vitro and In Situ Approaches to Measure Intestinal Permeability and Efflux Transporters |
|
|
331 | (16) |
|
10 In Silico Approaches to Predict Intestinal Permeability |
|
|
347 | (10) |
|
11 In Vivo Preclinical Approaches to Deconvolute The Contribution of First-Pass Effect from Oral Absorption |
|
|
357 | (20) |
|
12 In Vitro Approaches to Assess Hepatic Metabolism and First-Pass Effect |
|
|
377 | (10) |
|
13 The Utility of ECCS as a Roadmap to Improve Oral Bioavailability of New Molecular Entities: Industrial Perspective |
|
|
387 | (44) |
| Index |
|
431 | |
AYMAN F. EL-KATTAN, B. Pharm, PhD, is Associate Research Fellow in Pfizer's Pharmacokinetics, Dynamics, and Metabolism Department, Cambridge Laboratories and an Adjunct Professor at College of Pharmacy-University of Rhode Island in Rhode Island, US. Dr. El-Kattan is a reviewer for several journals and is an active member of the American Association of Pharmaceutical Scientists (AAPS). He serves on the executive committee of the Drug Transporter focus group. He has been invited speaker 50 times at national/international conferences and has published over 100 papers in peer-reviewed Journals, book chapters, and proceedings.
